Clinical Trial Update: Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating ATG-Fresenius for preventing acute graft-versus-host disease in matched unrelated donor stem cell transplantation has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• ATG-Fresenius (anti-thymocyte globulin)

Snippet

Sponsor: Neovii Biotech | Conditions: Graft vs Host Disease | Phase 3 | Status: COMPLETED